About QurAlis

At QurAlis, we are pioneering the path to conquering ALS and other neurodegenerative diseases with genetically validated targets with next-generation precision medicines. Our proprietary platforms and unique biomarkers enable the design and development of precision medicines that act directly on disease-causing genetic alterations.

We are advancing a deep pipeline of antisense oligonucleotides (ASOs) and small molecule programs addressing sub-forms of ALS that account for the majority of ALS patients. And, we are leveraging our insights, platforms, and successes in ALS to collaborate and expand our pipeline to other neurodegenerative diseases, such as frontotemporal-degeneration (FTD).

Our goal is to halt disease progression and significantly improve outcomes.

Our mission is to make a meaningful difference in patients’ lives.

That is QurAlis.

QurAlis was founded by Kasper Roet, Kevin Eggan and Clifford Woolf in 2016 to provide precision therapeutics that could benefit the entire ALS patient community.
ALS is not one disease, but a spectrum of disorders with varying underlying mechanisms.
QurAlis is developing precision therapeutics through technologies that allow us to investigate genetically validated targets in ALS patient-derived cells.
By attacking sub-forms of ALS, as well as frontotemporal dementia (FTD), one at a time, we can methodically address the broad spectrum of pathologies causing these diseases.

Our Company Values


We are pioneers in neurodegenerative disease biology, stem cell and ASO technology, biomarkers, and small molecule design. We invoke creativity to achieve success. We are at the forefront of developing cutting-edge precision medicine for neurodegenerative diseases. We dare to follow science and to break through existing barriers.

Urgency and Passion

We feel a great sense of urgency to bring our therapies to patients. To succeed in bringing new treatments to patients worldwide, we must remain honest and empathetic to our patient community, our science, our colleagues, and ourselves. Our passion and commitment motivate us by generating excitement and infusing energy in our work. We remain agile to ensure a rapid embrace of new scientific insights and technologies, and to persevere until we achieve our goal of bringing new hope to patients with ALS and other neurodegenerative diseases.

Diversity and Collaboration

The world’s biggest problems can only be solved by working together, in an environment that respects all ideas and contributors. Our strength comes from a foundation of world-renowned pioneers, team members and patient community members, all from various backgrounds and viewpoints. Our diversity guides our strategy and decision-making toward our goal of treating patients who come from all regions and social backgrounds across the world.


Precision and excellence are embedded in all layers of our organization as the hallmark of our methodology from discovery, research, and development, to patients. We believe that success in treating neurodegenerative diseases will be achieved by being precise - targeting the right patients, identifying the right disease mechanism, and carefully developing disease-modifying, clinically meaningful therapies to improve the lives of patients.